275. Deputy Johnny Guirke asked the Minister for Health regarding the reimbursement of Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s Ataxia (details supplied), the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) are being applied to this specific case, to prevent further delays in addressing the ‘unmet need’,; and if she will make a statement on the matter. [17395/26]

Summary

275. Deputy Johnny Guirke asked the Minister for Health regarding the reimbursement of Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s Ataxia (details supplied), the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) are being applied to this specific case, to prevent further delays in addressing the ‘unmet need’,; and if she will make a statement on the matter. [17395/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 4 March 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.